Search results
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
May 30, 2024 · Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. [5] Its main product is the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. [6]
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.
Novo Nordisk offers more than 20 medicines for diabetes, chronic weight management, rare bleeding disorders, hormone-related growth disorders and women’s health.
Novo Nordisk was named as the Best Place in the World to Work in 2022, but our people are what make our company what it is today, and will continue to shape our future. Discovering novel therapies to treat chronic disease for over 100 years. Learn who we are.
Apr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.
Jun 24, 2024 · COPENHAGEN/LONDON June 24 (Reuters) - Obesity drug-maker Novo Nordisk (NOVOb.CO) will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss ...
Jan 31, 2024 · Novo Nordisk on Wednesday forecast another year of double-digit growth as the Danish drugmaker began boosting U.S. supplies of its popular weight-loss drug Wegovy and pledged to roll out in new...
